Company Profiles

driven by the PitchBook Platform

Adrenergics

Description

Developer of novel therapeutics designed to treat dilated cardiomyopathy (DCM). The company's therapeutics focuses on developing medicines that are expected to modulate disease progression leading to improved outcomes, enabling patients to overcome difficult-to-treat situations.

2015

Founded

PRIVATE

Status

Series A

Latest Deal Type

$3M

Latest Deal Amount

$3M

Total Amount Raised

2

Investors

Description

Developer of novel therapeutics designed to treat dilated cardiomyopathy (DCM). The company's therapeutics focuses on developing medicines that are expected to modulate disease progression leading to improved outcomes, enabling patients to overcome difficult-to-treat situations.

Ownership Status

Privately Held (backing)

Financing Status

Venture Capital-Backed

Primary Industry

Biotechnology

Other Industries

Pharmaceuticals
Drug Discovery

Primary Office

San Diego, CA United States
    Request a free trial to the PitchBook Platform
    You're viewing a free company profile from the PitchBook Platform. To explore Adrenergics's full profile, request a free trial.

    Adrenergics Valuation and Funding

    Request access
    Deal TypeDateAmountRaised to DatePost-ValStatusStage

    Adrenergics Cap Table

    Stock# of Shares
    Authorized
    Par ValueDividend Rate (%)Original
    Issue Price
    LiquidationLiquidation
    Pref. Multiple
    Conversion
    Price
    % Owned

    Adrenergics Investors (2)

    Request access
    Investor NameInvestor TypeHoldingInvestor SinceParticipating RoundsBoard
    Seat
    Contact
    Info
    Avalon VenturesVenture CapitalMinority000 0000000 0000
    GSKCorporationMinority000 0000000 0000
    Avalon Ventures Venture Capital
    GSK Corporation
    Request full access to PitchBook